Analysts Conflicted on These Healthcare Names: Raffles Medical Group (OtherRAFLF), IDEAYA Biosciences (IDYA) and Alkermes (ALKS)
at www.tipranks.com (Wed, 29-Jul 6:10 AM)
IDEAYA Biosciences: Buy Rating Reiterated as Precision Oncology Pipeline Advances and $62 Price Target Maintained
at www.tipranks.com (Mon, 27-Jul 7:55 AM)
IDEAYA Launches Phase 1/2 IDE892 Combination Study Targeting MTAP-Deleted Pancreatic and Lung Cancers
Market Chameleon (Mon, 15-Jun 8:40 AM)
IDYA Raises $300 Million in Oversized Stock and Pre-Funded Warrant Offering—What Does This Signal for the Company’s Growth Path?
Market Chameleon (Tue, 9-Jun 7:06 AM)
